Skip to Content

Ibrutinib (Imbruvica) and Rituximab (Rituxan)

Treatment Given by Infusion, Treatment Given by Injection, Treatment Taken by Mouth

Generic : Ibrutinib (i-BROO-tih-nib) and Rituximab (rih-TUK-sih-mab)
Brand : Imbruvica (im-BROO-vih-kuh) and Rituxan (rih-TUK-sun)
Download In :
Download 0.4MB
Last Update : March 10, 2026

About this Treatment

The combination of ibrutinib and rituximab is used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM).

What are Patient Education Sheets (PES)?

A Patient Education Sheet (PES) is a practical tool created with the unique needs of patients with cancer in mind. Each sheet translates complex treatment information into clear, patient-friendly language. They provide easy-to-follow medication schedules and guidance on managing potential side effects, helping patients and their caregivers feel informed and supported.

These resources are pulled directly by healthcare providers, who can download and print them for distribution during patient visits. This ensures that patients and caregivers leave the clinic with a reliable, easy-to-understand reference tailored to their treatment.

In addition to the standard content, PES documents are also editable in designated sections. Providers can add personalized details such as counseling notes, local resources, or contact information, making each sheet specific to the patient’s care journey.